Skip to main content

Table 2 Frequency of anti-endothelial cell antibodies (AECA) and AECA titers in patients with Susac syndrome (SuS) and controls according to cut-off levels

From: Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study

  AECA, patients (%)   AECA, samples (%)   AECA, median titers AECA, titer ranges
  AECA ≥1:10      
Definite SuS 7/20 (35) P = 0.036c,d 11/32 (34) P = 0.012c,d 1:3200 1:100 – 1:17,500
Limited SuS 0/5 (0) 0/5 (0) N.a. N.a.
Controls 8/70 (11) 8/70 (11) 1:100 1:10 – 1:320
  HC 2/20 (10) 2/20 (10) 1:55 1:10 – 1:100
  MS 4a/25 (16) 4/25 (16) 1:210 1:10 – 1:320
  CTD 2b/25 (8) 2/25 (8) 1:165 1:10 – 1:320
  AECA >1:100      
Definite SuS 5/20 (25) P = 0.015c,d 9/32 (28) P = 0.002c,d 1:3200 1:100 – 1:17,500
Limited SuS 0/5 (0) 0/5 (0) N.a. N.a.
Controls 3/70 (4) 3/70 (4) 1:320 1:320 – 1:320
  HC 0/20 (0) 0/20 (0) N.a. N.a.
  MS 2/25 (8) 2/25 (8) 1:320 1:320 – 1:320
  CTD 1/25 (4) 1/25 (4) 1:320 1:320
  AECA >1:320      
Definite SuS 3/20 (15) P = 0.01c,d 7/32 (22) P < 0.0002c,d 1:7500 1:1000 – 1:17,500
Limited SuS 0/5 (0) 0/5 (0) N.a. N.a.
Controls 0/70 (0) 0/70 (0) N.a. N.a.
  HC 0/20 (0) 0/20 (0) N.a. N.a.
  MS 0/25 (0) 0/25 (0) N.a. N.a.
  CTD 0/25 (0) 0/25 (0) N.a. N.a.
  1. a3 × RRMS, 1 × PPMS. b1 × SLE, 1 × Sjögren syndrome. cFisher’s exact test. dDefinite SuS vs controls. N.a. = not applicable.